BEACHBODY ULTIMATE RESET TM (GBI-30, 6086)
Testo originale in francese.
Prodotto naturale per la salute autorizzato in Canada
Se questo prodotto fosse venduto in Francia
Nessun punto rilevato secondo le norme che applichiamo.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte | Massimo giornaliero, adulto |
|---|---|---|
| Sulfone de diméthyl Fonte : Sulfone de diméthyl | 125 mg | Non calcolata |
| Triticum aestivum Fonte : Leaf young | 550 mg | Non calcolata |
| Triacylglycérol lipase Fonte : Aspergillus niger - En entier | 2,5 mg | Non calcolata |
| Bioflavonoïdes d'agrumes Fonte : Citrus sinensis - Écorce de fruit | 15 mg | Non calcolata |
| Bioflavonoïdes d'agrumes Fonte : Citrus limon - Pelure (fruit) | 15 mg | Non calcolata |
| Bioflavonoïdes d'agrumes Fonte : Citrus paradisi - Pelure (fruit) | 15 mg | Non calcolata |
| papaïne Fonte : Carica papaya - Latex | 15 mg | Non calcolata |
| Triacylglycérol lipase Fonte : Aspergillus niger - En entier | 25 Unités de lipase FIP | Non calcolata |
| Myrciaria dubia Fonte : Fruit Potenza : 20 % vitamin C | 125 mg | Non calcolata |
| Triticum turgidum subsp. durum Fonte : Leaf young | 100 mg | Non calcolata |
| Curcuma longa Fonte : Rhizome Rapporto di estrazione : 65:1 Equivalente di pianta secca : 7.527 mg Potenza : 95 % Curcuminoids | 115,8 mg | Non calcolata |
| Serrapeptase Fonte : Serratia - Cellule entière | 7.500 SPU | Non calcolata |
Ingredienti non medicinali
Silice, Saveur de citron, Maltodextrine, Hydroxypropylméthylcellulose, Hypromellose, Feuille de stevia rebaudiana
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes | Non précisée | 1 Capsule | 1 Tous les jours |
| Adultes | Non précisée | 2 Capsule | 3 Tous les jours |
| Adultes | Non précisée | 1 packet | 3 Tous les jours |
| Adultes | Non précisée | 1 packet | 1 Tous les jours |
| Adultes | Non précisée | 0,8 g | 4 Tous les jours |
Usi autorizzati in Canada
Helps in weight management when used with a program of reduced intake of dietary calories. Probiotics that temporarily modify gut flora. Provides antioxidants.
Testo originale in inglese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Cautions and Warnings : Consult a health care practitioner prior to use if you are pregnant or breastfeeding. If you have high blood pressure, consult a health care practitioner prior to use. Hypersensitivity has been known to occur, in which case; discontinue use. Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family. Consult a health care practitioner immediately if you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking the product. Consult a health care practitioner prior to use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or have failed to defaecate following the use of a laxative product. Consult a health care practitioner prior to use if you are taking medications which inhibit peristaltic movement (e.g. opioids, loperamide). Consult a health care practitioner prior to use if you have diabetes. Consult a health care practitioner prior to use if you have difficulty swallowing. Consult a health care practitioner prior to use if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, diseases of the oesophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis). May cause temporary gas and bloating. Consult a health care practitioner prior to use if you are taking anticoagulant or antihypertensive medications. If you suffer from an immune system disorder (e.g. Crohn's disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, HIV/AIDS, etc.), caner, asthma, are taking immunosuppressants or have severe allergies, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have gallstones or a bile duct obstruction. Consult a health care practitioner prior to use if you have stomach ulcers or excess stomach acid. Hypersensitivity, such as allergy, has been known to occur, in which case, discontinue use. If you have gastrointestinal lesions/ulcers, are taking anticoagulant agents or anti-inflammatory agents, or are having surgery, consult a health care practitioner prior to use. Some people may experience mild gastrointestinal bloating, constipation or indigestion. Hypersensitivity/allergy is known to occur, in which case, discontinue use. Consult a health care practitioner prior to use if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. Consult a health care practitioner prior to use if you have a kidney disorder, or are taking cariac medications (e.g. cardiac glycosides or antiarrhythmic medications). Consult a health care practitioner prior to use if you have a faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease, (e.g. Crohn's disease or ulcerative colitis), abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes, hemorrhoids or diarrhoea. Consult a health care practitioner prior to use if you are undergoing hormone replacement therapy (HRT) or taking birth control medication. Do not use if you a history of systemic lupus erythematosus.
Testo originale in inglese.
Scheda del prodotto
- Titolare
- Team Beachbody Canada LP
- NPN o DIN-HM
- 80055698
- Stato
- Licenza attiva
- Data della licenza
- 17 novembre 2014
- Data di revisione
- 2 febbraio 2023
- Forma
- Kit
- Via di somministrazione
- Orale
- Tipo di domanda
- Non traditionnelle
Fonte
Scheda ufficiale Health Canada, licenza 80055698
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- Curcuma longa
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
TURMERIC - CURCUMA LONGA - Oral
Via di somministrazione: Oral (ESCOP 2003; Blumenthal et al. 2000)
Precauzioni e avvertenze
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Fonti citate da Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Fonti citate da Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Fonti citate da Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Fonti citate da Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condizione di applicazione: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografia di Health Canada del 26 settembre 2025
Turmeric -CURCUMA LONGA - Topical
Precauzioni e avvertenze
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Controindicazioni
Do not use on deep or puncture wounds, animal bites or serious burns.
- Serrapeptase
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
SERRAPEPTASE
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).
Fonti citate da Health Canada (4)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Revisione sistematica
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Studio randomizzato
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Studio randomizzato
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Studio randomizzato
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).
Fonti citate da Health Canada (4)
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Studio randomizzato
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Revisione sistematica
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Studio randomizzato
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Studio randomizzato
Reazioni avverse note
Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).
Fonti citate da Health Canada (1)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Revisione sistematica
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.